J Korean Med Sci.  2022 May;37(18):e146. 10.3346/jkms.2022.37.e146.

A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction

• Cho MR
• Lee S
• Song SK

• KMID: 2529712
• DOI: http://doi.org/10.3346/jkms.2022.37.e146

Abstract

Sarcopenia is a progressive and generalized loss of skeletal muscle mass and function. The prevalence of sarcopenia was reported to be up to 29% in older persons in the community healthcare setting. Sarcopenia diagnosis is confirmed by the presence of low muscle mass plus low muscle strength or low physical performance. Sarcopenia management options include non-pharmacological and pharmacological approaches. Non-pharmacological approaches include resistance exercise and adequate nutrition. Of the two, resistance exercise is the standard non-pharmacological treatment approach for sarcopenia with significant positive evidence. Some dietary approaches such as adequate intake of protein, vitamin D, antioxidant nutrients, and long-chain polyunsaturated fatty acid have been shown to have positive effects against sarcopenia. Currently, no specific drugs have been approved by the Food and Drug Administration for the treatment of sarcopenia. However, several agents, including growth hormone, anabolic or androgenic steroids, selective androgenic receptor modulators, protein anabolic agents, appetite stimulants, myostatin inhibitors, activating II receptor drugs, β-receptor blockers, angiotensin-converting enzyme inhibitors, and troponin activators, are recommended and have been shown to have variable efficacy. Future research should focus on sarcopenia biological pathway and improved diagnostic approaches such as biomarkers for early detection, development of consistently pre-eminent treatment methods for severe sarcopenia patients, and establishing sensitive measures for predicting sarcopenia treatment response.

Keyword

Sarcopenia; Diagnosis; Treatment; Future

Figure

• 

  Fig. 1 Diagnostic process of sarcopenia using the Asian Working Group for Sarcopenia 2019 algorithm.ASM = appendicular skeletal muscle mass, DXA = dual energy X-ray absorptiometry, BIA = bioelectrical impedance analysis.

Reference

1. Rosenburg I. Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr. 1989; 50(5):1231–1233.

2. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127(5):Suppl. 990S–1S. PMID: 9164280.

3. Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab. 2010; 35(5):707–712. PMID: 20962927.

4. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001; 137(4):231–243. PMID: 11283518.

5. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int. 2010; 21(4):543–559. PMID: 19779761.

6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1):16–31. PMID: 30312372.

7. Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014; 43(6):748–759. PMID: 25241753.

8. Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, van Loon LJ. Satellite cells in human skeletal muscle; from birth to old age. Age (Dordr). 2014; 36(2):545–547. PMID: 24122288.

9. Frontera WR, Zayas AR, Rodriguez N. Aging of human muscle: understanding sarcopenia at the single muscle cell level. Phys Med Rehabil Clin N Am. 2012; 23(1):201–207. PMID: 22239884.

10. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol. 2013; 45(10):2191–2199. PMID: 23702032.

11. Edström E, Altun M, Bergman E, Johnson H, Kullberg S, Ramírez-León V, et al. Factors contributing to neuromuscular impairment and sarcopenia during aging. Physiol Behav. 2007; 92(1-2):129–135. PMID: 17585972.

12. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018; 8:1960. PMID: 29375577.

13. Walrand S, Zangarelli A, Guillet C, Salles J, Soulier K, Giraudet C, et al. Effect of fast dietary proteins on muscle protein synthesis rate and muscle strength in ad libitum-fed and energy-restricted old rats. Br J Nutr. 2011; 106(11):1683–1690. PMID: 21736767.

14. Huang JH, Hood DA. Age-associated mitochondrial dysfunction in skeletal muscle: Contributing factors and suggestions for long-term interventions. IUBMB Life. 2009; 61(3):201–214. PMID: 19243006.

15. Ferri E, Marzetti E, Calvani R, Picca A, Cesari M, Arosio B. Role of age-related mitochondrial dysfunction in sarcopenia. Int J Mol Sci. 2020; 21(15):5236–5247.

16. Ji LL. Exercise at old age: Does it increase or alleviate oxidative stress? Ann N Y Acad Sci. 2001; 928(1):236–247. PMID: 11795515.

17. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412–423. PMID: 20392703.

18. Schaap LA, van Schoor NM, Lips P, Visser M. Associations of sarcopenia definitions, and their components, with the incidence of recurrence falling and fractures: the longitudinal aging study in Amsterdam. J Gerontol A Biol Sci Med Sci. 2018; 73(9):1199–1204. PMID: 29300839.

19. Ibrahim K, May C, Patel HP, Baxter M, Sayer AA, Roberts H. A feasibility study of implementing grip strength measurement into routine hospital practice (GRImP): study protocol. Pilot Feasibility Stud. 2016; 2(1):27. PMID: 27965846.

20. Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A Jr, Orlandini A, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015; 386(9990):266–273. PMID: 25982160.

21. Schaap LA, Koster A, Visser M. Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. Epidemiol Rev. 2013; 35(1):51–65. PMID: 23221972.

22. Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 2018; 9(2):269–278. PMID: 29349935.

23. Masanés F, Rojano I Luque X, Salvà A, Serra-Rexach JA, Artaza I, Formiga F, et al. Cut-off points for muscle mass-not grip strength or gait speed-determine variations in sarcopenia prevalence. J Nutr Health Aging. 2017; 21(7):825–829. PMID: 28717813.

24. Treviño-Aguirre E, López-Teros T, Gutiérrez-Robledo L, Vandewoude M, Pérez-Zepeda M. Availability and use of dual energy X-ray absorptiometry (DXA) and bio-impedance analysis (BIA) for the evaluation of sarcopenia by Belgian and Latin American geriatricians. J Cachexia Sarcopenia Muscle. 2014; 5(1):79–81. PMID: 24442632.

25. Bahat G, Yilmaz O, Kılıç C, Oren MM, Karan MA. Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging. 2018; 22(8):898–903. PMID: 30272090.

26. Ishii S, Tanaka T, Shibasaki K, Ouchi Y, Kikutani T, Higashiguchi T, et al. Development of a simple screening test for sarcopenia in older adults. Geriatr Gerontol Int. 2014; 14(Suppl 1):93–101. PMID: 24450566.

27. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011; 40(4):423–429. PMID: 21624928.

28. Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016; 16(1):170. PMID: 27716195.

29. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999; 70(2):113–119. PMID: 10380242.

30. Cooper C, Fielding R, Visser M, van Loon LJ, Rolland Y, Orwoll E, et al. Tools in the assessment of sarcopenia. Calcif Tissue Int. 2013; 93(3):201–210. PMID: 23842964.

31. Cawthon PM, Peters KW, Shardell MD, McLean RR, Dam TT, Kenny AM, et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014; 69(5):567–575. PMID: 24737559.

32. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997–1006. PMID: 18923576.

33. Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer. J Thorac Oncol. 2015; 10(12):1795–1799. PMID: 26484630.

34. Lee SJ, Janssen I, Heymsfield SB, Ross R. Relation between whole-body and regional measures of human skeletal muscle. Am J Clin Nutr. 2004; 80(5):1215–1221. PMID: 15531668.

35. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010; 91(4):1133S–7S. PMID: 20164322.

36. Kim KM, Jang HC, Lim S. Differences among skeletal muscle mass indices derived from height-, weight-, and body mass index-adjusted models in assessing sarcopenia. Korean J Intern Med. 2016; 31(4):643–650. PMID: 27334763.

37. Tosato M, Marzetti E, Cesari M, Savera G, Miller RR, Bernabei R, et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging Clin Exp Res. 2017; 29(1):19–27. PMID: 28176249.

38. Landi F, Onder G, Russo A, Liperoti R, Tosato M, Martone AM, et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr. 2014; 33(3):539–544. PMID: 23948128.

39. Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009; 13(10):881–889. PMID: 19924348.

40. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geriatric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci. 2013; 68(1):39–46. PMID: 22923430.

41. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA. 2011; 305(1):50–58. PMID: 21205966.

42. Maggio M, Ceda GP, Ticinesi A, De Vita F, Gelmini G, Costantino C, et al. Instrumental and non-instrumental evaluation of 4-m walking speed in older individuals. PLoS One. 2016; 11(4):e0153583. PMID: 27077744.

43. Rydwik E, Bergland A, Forsén L, Frändin K. Investigation into the reliability and validity of the measurement of elderly people’s clinical walking speed: a systematic review. Physiother Theory Pract. 2012; 28(3):238–256. PMID: 21929322.

44. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991; 39(2):142–148. PMID: 1991946.

45. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15(2):95–101. PMID: 24461239.

46. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus updated on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020; 21(3):300–307.e2. PMID: 32033882.

47. Chen LK, Lee WJ, Peng LN, Liu LK, Arai H, Akishita M, et al. Recent advances in sarcopenia research in Asia: 2016 update from the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2016; 17(8):767.e1–767.e7.

48. Faulkner JA, Larkin LM, Claflin DR, Brooks SV. Age-related changes in the structure and function of skeletal muscles. Clin Exp Pharmacol Physiol. 2007; 34(11):1091–1096. PMID: 17880359.

49. Ryall JG, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology. 2008; 9(4):213–228. PMID: 18299960.

50. Han JW, Kim DI, Nam HC, Chang UI, Yang JM, Song DS. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis. Clin Mol Hepatol. 2022; 28(2):219–231. PMID: 34281295.

51. Lin B, Bai L, Wang S, Lin H. The association of systemic interleukin 6 and interleukin 10 levels with sarcopenia in elderly patients with chronic obstructive pulmonary disease. Int J Gen Med. 2021; 14:5893–5902. PMID: 34566428.

52. Choi K, Jang HY, Ahn JM, Hwang SH, Chung JW, Choi YS, et al. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2020; 26(4):492–505. PMID: 32646201.

53. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003; 58(10):M911–M916. PMID: 14570858.

54. Patel HP, Jameson KA, Syddall HE, Martin HJ, Stewart CE, Cooper C, et al. Developmental influences, muscle morphology, and sarcopenia in community-dwelling older men. J Gerontol A Biol Sci Med Sci. 2012; 67A(1):82–87.

55. Petermann-Rocha F, Chen M, Gray SR, Ho FK, Pell JP, Celis-Morales C. Factors associated with sarcopenia: a cross-sectional analysis using UK Biobank. Maturitas. 2020; 133:60–67. PMID: 32005425.

56. Robinson SM, Reginster JY, Rizzoli R, Shaw SC, Kanis JA, Bautmans I, et al. Does nutrition play a role in the prevention and management of sarcopenia? Clin Nutr. 2018; 37(4):1121–1132. PMID: 28927897.

57. Valenzuela T. Efficacy of progressive resistance training interventions in older adults in nursing homes: a systematic review. J Am Med Dir Assoc. 2012; 13(5):418–428. PMID: 22169509.

58. Suetta C, Andersen JL, Dalgas U, Berget J, Koskinen S, Aagaard P, et al. Resistance training induces qualitative changes in muscle morphology, muscle architecture, and muscle function in elderly postoperative patients. J Appl Physiol (1985). 2008; 105(1):180–186. PMID: 18420714.

59. McKendry J, Currier BS, Lim C, Mcleod JC, Thomas AC, Phillips SM. Nutritional supplements to support resistance exercise in countering the sarcopenia of aging. Nutrients. 2020; 12(7):2057.

60. Gryson C, Ratel S, Rance M, Penando S, Bonhomme C, Le Ruyet P, et al. Four-month course of soluble milk proteins interacts with exercise to improve muscle strength and delay fatigue in elderly participants. J Am Med Dir Assoc. 2014; 15(12):958.e1–958.e9. PMID: 25444576.

61. Martínez-Arnau FM, Fonfría-Vivas R, Buigues C, Castillo Y, Molina P, Hoogland AJ, et al. Effects of leucine administration in sarcopenia: a randomized and placebo-controlled clinical trial. Nutrients. 2020; 12(4):932.

62. Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015; 16(9):740–747. PMID: 26170041.

63. Yoo JI, Chung HJ, Kim BG, Jung YK, Baek KW, Song MG, et al. Comparative analysis of the association between various serum vitamin D biomarkers and sarcopenia. J Clin Lab Anal. 2021; 35(9):e23946. PMID: 34350631.

64. Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int J Endocrinol. 2012; 2012:127362. PMID: 22690213.

65. Meriggioli MN, Roubenoff R. Prospect for pharmacological therapies to treat skeletal muscle dysfunction. Calcif Tissue Int. 2015; 96(3):234–242. PMID: 25363509.

66. Morley JE. Should frailty be treated with testosterone? Aging Male. 2011; 14(1):1–3. PMID: 20670101.

67. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Lessons from the testosterone trials. Endocr Rev. 2018; 39(3):369–386. PMID: 29522088.

68. Rondanelli M, Miccono A, Peroni G, Guerriero F, Morazzoni P, Riva A, et al. A systematic review on the effects of botanicals on skeletal muscle health in order to prevent sarcopenia. Evid Based Complement Alternat Med. 2016; 2016:5970367. PMID: 27051451.

69. Argiles JM, Stemmler B. The potential of ghrelin in the treatment of cancer cachexia. Expert Opin Biol Ther. 2013; 13(1):67–76. PMID: 23078025.

70. Morley JE. Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int. 2016; 98(4):319–333. PMID: 26100650.

71. Jang J, Park S, Kim Y, Jung J, Lee J, Chang Y, et al. Myostatin inhibition-induced increase in muscle mass and strength was amplified by resistance exercise training, and dietary essential amino acids improved muscle quality in mice. Nutrients. 2021; 13(5):1508. PMID: 33947024.

72. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011; 2(3):143–151. PMID: 21966641.

73. Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016; 7(3):355–365. PMID: 27386169.

74. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart. 2002; 88(4):373–377. PMID: 12231595.

75. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014; 9(5):e96921. PMID: 24805850.

76. Liccini A, Malmstrom TK. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J Am Med Dir Assoc. 2016; 17(9):846–851. PMID: 27569712.

77. Chung SM, Moon JS, Chang MC. Prevalence of sarcopenia and its association with diabetes: a meta-analysis of community-dwelling Asian population. Front Med (Lausanne). 2021; 8:681232. PMID: 34095184.

78. van de Bool C, Rutten EP, van Helvoort A, Franssen FM, Wouters EF, Schols AM. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle. 2017; 8(5):748–758. PMID: 28608438.

79. Kim SH, Shin MJ, Shin YB, Kim KU. Sarcopenia associated with chronic obstructive pulmonary disease. J Bone Metab. 2019; 26(2):65–74. PMID: 31223602.

80. Dodds RM, Davies K, Granic A, Hollingsworth KG, Warren C, Gorman G, et al. Mitochondrial respiratory chain function and content are preserved in the skeletal muscle of active very old men and women. Exp Gerontol. 2018; 113:80–85. PMID: 30266472.